Skip to main content

MOTS-c vs Humanin

Both MOTS-c and Humanin are used for longevity. Here's how their evidence, dosing, and regulatory status actually compare.

MOTS-c

Evidence B

Mitochondrial-derived peptide MOTS-c

A 16-amino-acid mitochondrial-derived peptide that improves insulin sensitivity and exercise capacity in animal models. Among the most promising 'mitokines' for metabolic aging.

View full MOTS-c profile →

Humanin

Evidence B

Humanin (HN)

A 24-amino-acid mitochondrial-derived peptide with cytoprotective effects across Alzheimer's, diabetes, and atherosclerosis preclinical models. Endogenous levels decline sharply with age.

View full Humanin profile →

Side-by-Side

AttributeMOTS-cHumanin
Evidence GradeBB
FDA StatusNot FDA-approved — research peptide; multiple early-phase clinical trialsNot FDA-approved — mitochondrial-derived peptide research compound
Typical Dose5–10 mg, 2–3 times weekly (subcutaneous)Research range: 0.5–1 mg subcutaneous (rare clinical use)
Clinics Indexed225
Categoriesmetabolic, longevitymitochondrial, longevity, neuroprotection

Key reported benefits — MOTS-c

  • Insulin sensitivity
  • Exercise capacity
  • Metabolic flexibility

Key reported benefits — Humanin

  • Cytoprotection
  • Anti-amyloid effects
  • Insulin sensitization

Educational use only

This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.

← Back to all comparisons